ONCO/RESOLVE
DEAD

Serial Number

87619641

Owner

Pillar Biosciences, Inc.

Attorney

Marcus Assefa

Filing Date

Sep 22, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ONCO/RESOLVE Trademark

Serial Number: 87619641

ONCO/RESOLVE is a trademark filed by Pillar Biosciences, Inc. on September 22, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Pillar Biosciences, Inc. (17 trademarks)

Natick, MA 01760

Entity Type: 03

Trademark Details

Filing Date

September 22, 2017

Registration Date

Not Registered

Published for Opposition

March 20, 2018

Goods & Services

Computer software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; computer software for analyzing biological samples; computer software for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; computer software for use with reagents and reagent kits, all for use in detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; computer software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing

Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, buffers, and adhesive reagent labels, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being for medical diagnostic purposes; Biological and biochemical reagents used for selectively amplifying nucleic acid fragments, with the aforementioned reagents being used for medical diagnostic purposes; Biological and biochemical kits comprised of diagnostic preparations for medical purposes, namely, for the diagnosis and treatment of cancer

Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, buffers, and adhesive reagent labels, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being in the fields of scientific research, clinical research, and scientific diagnostics research; Biological and biochemical reagents used for selectively amplifying nucleic acid fragments for scientific research, clinical research, and scientific diagnostics research

Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; medical diagnostic testing in the nature of providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of medical diagnostics

Software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others with reagents and reagent kits, all for use in detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; software as a service (Saas), namely, hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; scientific research, namely, collection, management, and analysis of data in the fields of scientific research, clinical research and scientific diagnostics; providing biological sample testing services for others in the fields of scientific research, clinical research and scientific diagnostics; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, and scientific diagnostics research; genetic testing for scientific research purposes in the nature of providing bioinformatics and gene expression microarray image analysis services for others, namely, performing gene expression quantification, gene image processing, and gene information processing for others; medical diagnostic research, namely, collection, management, and analysis of data in the field of medical diagnostics

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 17, 2019 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 17, 2019 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 17, 2018 EXRA
SOU EXTENSION 1 GRANTED
Nov 15, 2018 EX1G
SOU EXTENSION 1 FILED
Nov 15, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 15, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 15, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 20, 2018 NPUB
PUBLISHED FOR OPPOSITION
Mar 20, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 28, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 8, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 25, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 24, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 24, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 4, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 4, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 4, 2018 CNRT
ASSIGNED TO EXAMINER
Dec 28, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2017 NWOS
NEW APPLICATION ENTERED
Sep 26, 2017 NWAP